Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.

By H. Maeda. Bioconjugate chemistry, 2010

979 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/4955111f08636c2de0d99c087d63c17d2f3a05a9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Hisataka Kobayashi
2. R. Watanabe
3. Peter L. Choyke
4. O. Farokhzad
5. W. Choi
6. Basit Yameen
7. C. Vilos
8. A. Swami

In Molecular Biology

1. Anil Sood
2. Gabriel Lopez-Berestein
3. Peter L. Choyke
4. O. Farokhzad
5. Hisataka Kobayashi
6. W. Choi
7. Linlin Wang
8. George A. Calin

In Physiology

1. O. Farokhzad
2. W. Choi
3. Basit Yameen
4. C. Vilos
5. A. Swami
6. Jinjun Shi

Citations in the corpus

• Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? (2013, background): “(12) Most nano-sized agents accumulate within tumors due to the EPR effect and then release their therapeutic payloads.”
• Insight into nanoparticle cellular uptake and intracellular targeting (2014, positive): “The groundbreaking discovery of the EPR effect [13,14] associated with the tumor because of the abnormal and leaky microvasculature has emerged as the foundation for the passively targeted first generation of nanomedicines preferentially accumulating in tumor tissue [15, 16].”
• RNA interference in the clinic: challenges and future directions (2010, background): “Another important factor for increased capillary leak is the enhanced permeability and retention (EPR) effect, which can be exploited and enhanced for improved nanoparticle deliver”